Background
Materials and methods
Patients
Construction and validation of HGS
Functional annotation and analysis
Statistical analysis
Results
The establishment of HGS
Validation of HGS
Characteristic | TCGA | CIT/GSE39582 | Meta-validation |
---|---|---|---|
Number of patients | 624 | 566 | 687 |
Patients with survival data | 509 | 557 | 590 |
Mean age, years | 66.27 ± 12.76 | 66.85 ± 13.29 | 66.80 ± 12.82 |
Gender, n | |||
Male | 332 | 310 | 371 |
Female | 292 | 256 | 316 |
TNM stage, n | |||
Stage I | 105 | 33 | 68 |
Stage II | 230 | 264 | 314 |
Stage III | 180 | 205 | 205 |
Stage IV | 88 | 60 | 100 |
NA | 21 | 4 | 0 |
CMS system, n | |||
CMS1 | 68 | 91 | 126 |
CMS2 | 207 | 232 | 252 |
CMS3 | 64 | 69 | 103 |
CMS4 | 117 | 127 | 155 |
NA | 168 | 47 | 51 |
Tumor location, n | |||
Left | 354 | 342 | 233 |
Right | 270 | 224 | 185 |
NA | 269 | ||
RFS event, n | |||
Yes | 100 | 177 | 141 |
No | 416 | 380 | 449 |
NA | 108 | 9 | 97 |
OS event, n | |||
Yes | 67 | 191 | 73 |
No | 557 | 371 | 104 |
NA | 4 | 220 | |
DFS event, n | |||
Yes | 146 | 248 | 188 |
No | 386 | 314 | 434 |
NA | 92 | 4 | 65 |
MMR status, n | |||
MSI | 189 | 75 | 25 |
MSS | 431 | 444 | 65 |
NA | 4 | 47 | 597 |
CIMP status, n | |||
Positive | 91 | 26 | |
Negative | 405 | 64 | |
NA | 624 | 70 | 597 |
CIN status, n | |||
Positive | 353 | ||
Negative | 110 | ||
NA | 624 | 103 | 687 |
TP53 status, n | |||
Wild type | 161 | ||
Mutation | 190 | ||
NA | 624 | 215 | 687 |
KRAS status, n | |||
Wild type | 34 | 328 | 70 |
Mutation | 30 | 217 | 20 |
NA | 560 | 21 | 597 |
BRAF status, n | |||
Wild type | 32 | 461 | 73 |
Mutation | 3 | 51 | 17 |
NA | 589 | 54 | 597 |
Characteristic | CIT/GSE39582 CRC | TCGA CRC | Meta-validation | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||
HR (95% CI) | P-value | HR (95%CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
HGS | 8.66 (4.37–17.17) | < 0.001 | 7.54 (3.78–15.06) | < 0.001 | 2.59 (1.08–6.25) | 0.04 | 2.59 (1.08–6.25) | 0.04 | 8.25 (3.09–22.03) | < 0.001 | 7.25 (2.72–19.29) | < 0.001 |
Age | 1.01 (0.99 –1.03) | 0.58 | 1.01 (0.98–1.04) | 0.37 | 0.97 (0.95–1.00) | 0.02 | 0.98 (0.96–1.00) | 0.05 | ||||
Gender | 1.53 (0.898–2.62) | 0.12 | 1.56 (0.81–2.99) | 0.18 | 0.68 (0.39–1.16) | 0.15 | ||||||
TNM stage | 7.89 (1.11–55.91) | < 0.001 | 5.76 (0.81–41.12) | 0.08 | 1.83 (0.76–4.41) | 0.17 | 3.99 (1.24–12.80) | 0.01 | 3.73 (1.16–11.99) | 0.03 | ||
Tumor location | 1.08 (0.64–1.84) | 0.78 | 1.09 (0.59–2.04) | 0.78 | 1.30 (0.57–2.99) | 0.53 | ||||||
MMR status | 1.63 (0.70–3.82) | 0.25 | 0.64 (0.34–1.24) | 0.18 | 1.27 (0.42–3.86) | 0.67 | ||||||
CIMP status | 0.95 (0.44–2.02) | 0.89 | 0.91 (0.32–2.55) | 0.85 | ||||||||
CIN status | 1.69 (0.75–3.81) | 0.20 | ||||||||||
TP53 mutation | 1.39 (0.78–2.48) | 0.27 | ||||||||||
KRAS mutation | 1.44 (0.86–2.40) | 0.16 | 1.02 (0.23–4.60) | 0.98 | 1.40 (0.50–3.94) | 0.52 | ||||||
BRAF mutation | 1.42 (0.57–3.58) | 0.45 | 1.72(0.61–4.81) | 0.30 |
Cohorts | HGS | Oncotype DX | ||
---|---|---|---|---|
C-index | 95% CI | C-index | 95% CI | |
CIT/GSE39582 (training) | 0.80 | 0.70–0.90 | 0.65 | 0.53–0.77 |
TCGA (validation) | 0.70 | 0.55–0.85 | 0.61 | 0.44–0.77 |
Meta-validation | 0.68 | 0.55–0.80 | 0.73 | 0.64–0.83 |